Type of assessment | Cutoff | Sensitivity | Specificity | PPV | NPV | Accuracy | 2-y survival | P* |
Sex | Female | 80% | 71% | 67% | 83% | 75% | 14% | 0.006 |
Male | 83% | |||||||
IPI | low = 0, 1 | 80% | 57% | 57% | 80% | 67% | 70% | 0.038 |
high = 2–5 | 39% | |||||||
Ann Arbor stage | low = I/II | 70% | 64% | 58% | 75% | 67% | 67% | 0.034 |
high = IV | 37% | |||||||
DS at midtreatment | low = 1–3 | 63% | 94% | 83% | 83% | 83% | 62% | 0.001 |
high = 4, 5 | 17% | |||||||
SUVmax at pretreatment | low < 7.55 | 50% | 50% | 42% | 58% | 50% | 55% | 0.875 |
high > 7.55 | 51% | |||||||
SUVmax at midtreatment | low < 3 | 63% | 94% | 83% | 83% | 83% | 62% | 0.001 |
high > 3 | 17% | |||||||
ΔSUVmax (pretreatment compared with midtreatment) | >88% | 80% | 7% | 38% | 33% | 38% | 0% | 0.588 |
<88% | 59% | |||||||
DS at end-treatment | low = 1–3 | 40% | 100% | 100% | 80% | 82% | 68% | <0.001 |
high = 4, 5 | 0% | |||||||
SUVmax at end-treatment | low < 2 | 20% | 92% | 50% | 73% | 71% | 61% | 0.318 |
high > 2 | 50% | |||||||
ΔSUVmax (pretreatment compared with end-treatment) | >88% | 80% | 33% | 33% | 80% | 47% | 67% | 0.400 |
<88% | 57% |
↵* P value based on Kaplan–Meier analysis.